Study reports immune and T-cell response from CanSino COVID-19 vaccine candidate.
A July 20, 2020 article in The Lancet reported that the results of a trial for CanSino Biologics’ COVID-19 vaccine showed the non-replicating adenovirus type-5 (Ad5)-vectored vaccine was safe and induced “significant immune responses in the majority of recipients after a single immunization.”
The randomized, double-blind, placebo-controlled, Phase II trial of the vaccine was conducted in Wuhan, China for more than 500 healthy adults aged 18 years or older. Participants received injections of 1×1011 viral particles per mL, 5×1010 viral particles per mL, or a placebo.
The vaccine induced neutralizing antibodies in 59% of the 1â×â1011 dose group participants and 47% of the 5×1010 dose group participants, and seroconversion of binding antibody in 96% of the 1×1011 dose group participants and 97% of the 5×1010 dose group participants.
Positive specific T-cell responses were found in 90% of participants in the 1×1011 dose group and 88% of participants in the 5×1010 dose group. 95% of participants in the 1×1011 dose group and 91% of the recipients in the 5×1010 dose group showed either cellular or humoral immune responses at day 28 post vaccination, according the article.
The authors noted that patient age and pre-existing anti-Ad5 immunity of the participants could have affected the candidate vaccine's safety and immunogenicity.
In a separate article published online in The Lancet on July 20, 2020, AstraZeneca reported that interim results from an ongoing Phase I/II trial of its AZD1222 vaccine candidate against the SARS-CoV-2 virus showed the vaccine was tolerated and generated immune responses in all evaluated patients.
Source: The Lancet
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 31st 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.